Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
Kristina L. Bajema, Kristin Berry, Elani Streja, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 6, pp. 807-816
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
Jennifer Hammond, Robert J. Fountaine, Carla Yunis, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1186-1195
Open Access | Times Cited: 59
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
William HK Schilling, Podjanee Jittamala, James A Watson, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 1, pp. 36-45
Open Access | Times Cited: 55
Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort study
Matthew S. Durstenfeld, Michael J. Peluso, Feng Lin, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 1
Open Access | Times Cited: 27
Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study
Huwen Wang, Yuchen Wei, C.T. Hung, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 10, pp. 1130-1140
Open Access | Times Cited: 13
Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study
Kristina L. Bajema, Lei Yan, Yuli Li, et al.
The Lancet Infectious Diseases (2025)
Closed Access | Times Cited: 1
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106708-106708
Open Access | Times Cited: 31
Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges
Dimitrios Tsilingiris, Natalia G. Vallianou, Ιrene Karampela, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10458-10458
Open Access | Times Cited: 30
Effectiveness of Nirmatrelvir–Ritonavir Against the Development of Post–COVID-19 Conditions Among U.S. Veterans
George N. Ioannou, Kristin Berry, Nallakkandi Rajeevan, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 11, pp. 1486-1497
Open Access | Times Cited: 23
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis
Juan Jiang, Yantong Li, Qiaoling Jiang, et al.
Journal of Infection (2024) Vol. 89, Iss. 2, pp. 106190-106190
Closed Access | Times Cited: 9
Clinical Risk and Outpatient Therapy Utilization for COVID-19 in the Medicare Population
Andrew D. Wilcock, Stephen M. Kissler, Ateev Mehrotra, et al.
JAMA Health Forum (2024) Vol. 5, Iss. 1, pp. e235044-e235044
Open Access | Times Cited: 8
Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 spike protein
H. Caohuy, Ofer Eidelman, Tinghua Chen, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Early biological markers of post-acute sequelae of SARS-CoV-2 infection
Scott Lu, Michael J. Peluso, David V. Glidden, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Economic burden of COVID-19 for employers and employees in the United States
Heather Sell, Kassandra Schaible, Julie Ann Gouveia-Pisano, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 267-278
Open Access | Times Cited: 6
Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review
A. Cha-Silva, M. Gavaghan, Tobias Bergroth, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 3, pp. e246-e257
Open Access | Times Cited: 5
Management of a COVID-19 outbreak using a multidisciplinary approach and infection prevention control practices at a community living center in Veterans Administration Hospital, North Texas
Ikwo Oboho, John Hanna, Denisse Silva-Rodriguez, et al.
Antimicrobial Stewardship & Healthcare Epidemiology (2025) Vol. 5, Iss. 1
Open Access
Long Covid in Older Adults: Functional Outcomes and Treatment Effectiveness
Brittin Wagner, Kate Mathers, Aaron Norfolk, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation
Yuchen Wei, Christopher Boyer, Katherine Min Jia, et al.
Emerging Microbes & Infections (2025)
Open Access
Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
Guozhang Lin, Yuchen Wei, Zihao Guo, et al.
Respiratory Research (2025) Vol. 26, Iss. 1
Open Access
Association between nirmatrelvir/ritonavir treatment and antibiotic prescribing in the outpatient setting among patients with COVID-19
Aisling R. Caffrey, Haley J. Appaneal, Vrishali V. Lopes, et al.
Microbiology Spectrum (2025)
Open Access
Pharmacologic Treatment and Management of Coronavirus Disease 2019
Amy Hirsch Shumaker, Adarsh Bhimraj
Infectious Disease Clinics of North America (2025)
Closed Access
Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
Lei Yan, Elani Streja, Yuli Li, et al.
JAMA Network Open (2023) Vol. 6, Iss. 8, pp. e2331249-e2331249
Open Access | Times Cited: 13
Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies
Kathiaja Miranda Souza, G. Carrasco, Robin Rojas-Cortés, et al.
PLoS ONE (2023) Vol. 18, Iss. 10, pp. e0284006-e0284006
Open Access | Times Cited: 12
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Yonatan Moges Mesfin, Joseph E. Blais, Kelemu Tilahun Kibret, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 9, pp. 2119-2131
Open Access | Times Cited: 4
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study
Carlo Torti, Pier Paolo Olimpieri, Paolo Bonfanti, et al.
The Lancet Regional Health - Europe (2023) Vol. 31, pp. 100684-100684
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top